Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine/D2 pathways

F Papaleo1, F Yang, S Garcia

  • 1Clinical Brain Disorders Branch, Genes, Cognition and Psychosis Program, National Institute of Mental Health, Bethesda, MD 20892, USA. francesco.papaleo@iit.it

Molecular Psychiatry
|October 20, 2010
PubMed

Insights

Dysbindin-1 deficiency in mice alters dopamine-related behaviors and impairs working memory, particularly under stress. This study reveals molecular and cellular changes in the medial prefrontal cortex linked to psychosis.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Psychiatry

Background:

  • Dysbindin-1 is linked to schizophrenia and regulates dopamine D2-receptor trafficking.
  • The precise molecular mechanisms connecting dysbindin-1 to schizophrenia's clinical symptoms remain unclear.

Purpose of the Study:

  • To investigate the role of dysbindin-1 in schizophrenia-related behaviors, medial prefrontal cortex (mPFC) function, and D2-receptor signaling in mice.
  • To explore how dysbindin-1 deficiency affects neural excitability and molecular pathways in the mPFC.

Main Methods:

  • Utilized dysbindin-1-deficient mice (dys-/-) to assess behavioral phenotypes.
  • Examined molecular and electrophysiological changes in the mPFC.
  • Investigated the impact of D2-receptor stimulation on behavior and neural activity.

Main Results:

  • Dysbindin-1 disruption altered dopamine-related behaviors and impaired working memory under stress.
  • Pyramidal neurons in the mPFC of dys-/- mice showed altered excitability.
  • Reduced expression of Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) and CaMKKβ was observed in the mPFC of dys-/- mice.
  • D2-receptor agonist treatment mimicked some molecular and behavioral effects.

Conclusions:

  • Dysbindin-1 modulates D2-receptor-related behaviors and cortical activity.
  • Cellular and molecular changes in the mPFC, including CaMK pathways, are implicated in the association between dysbindin-1 and psychosis.
  • Findings provide insights into the neurobiological underpinnings of schizophrenia.

Related Concept Videos

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Biological Causes of Schizophrenia01:29

Biological Causes of Schizophrenia

Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...